2,362 results on '"Kesselheim, Aaron S."'
Search Results
2. Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020
3. Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies
4. Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA
5. Evidence, Errors, and Ethics
6. Physician and Device Manufacturer Tort Liability for Remote Patient Monitoring Devices
7. The cost of drug patent expiration date errors
8. Biologic patent challenges under the America Invents Act
9. Independent Advice on Drug Approvals: an Investigation of EMA Practices
10. Approval and therapeutic value of gene therapies in the US and Europe
11. Experts’ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care
12. The prevalence of drug patent term extensions in the United States, 2000–2018
13. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma
14. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework
15. Rates and costs of drug testing practices for private payors in the outpatient setting in the United States, 2015–2019
16. Market dynamics of authorized generics in Medicaid from 2014 to 2020
17. Persistence of resistance: a panel data analysis of the effect of antibiotic usage on the prevalence of resistance
18. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
19. Alternatives to the quality-adjusted life year: How well do they address common criticisms?
20. Coverage of New Drugs in Medicare Part D
21. Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019
22. Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease
23. Patenting Strategies on Inhaler Delivery Devices
24. Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries
25. Pursuing Value-Based Prices for Drugs : A Comprehensive Comparison of State Prescription Drug–Pricing Boards
26. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone
27. Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD
28. Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010–2018
29. Regulating Laboratory Tests: What Framework Would Best Support Safety and Validity?
30. Global cooperation and early access—clinical outcomes matter
31. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis
32. New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence
33. State Laws and Generic Substitution in the Year After New Generic Competition
34. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis
35. The characteristics of patents impacting availability of biosimilars
36. Why France Spends Less Than the United States on Drugs : A Comparative Study of Drug Pricing and Pricing Regulation
37. Ensuring Patient Safety and Benefit in Use of Medical Devices Granted Expedited Approval
38. Lifecycle Regulation and Evaluation of Artificial Intelligence and Machine Learning-Based Medical Devices
39. Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?".
40. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
41. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.
42. Trust in the Food and Drug Administration: A National Survey Study.
43. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
44. Producing and using timely comparative evidence on drugs : lessons from clinical trials for covid-19
45. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines : retrospective cohort study
46. Accounting for US public funding in drug development : how can we better balance access, affordability, and innovation?
47. Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
48. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition
49. Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept
50. How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.